Johnson & Johnson has sued a U.S. government agency over a closely watched dispute focusing on payment methods for some ...

Researchers at the University of Copenhagen have developed a patch for easier and more effective treatment of psoriasis. The ...

We also discussed peptides and stem cells and how we can use all these cutting-edge treatments to optimize my health ... She ...

Medically reviewed by Casey Gallagher, MD Psoriasis of the hands and feet, known as palmoplantar psoriasis, is an inflammatory autoimmune disorder that causes scaly, itchy skin patches on the palms ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

THIS YEAR saw the 33rd European Academy of Dermatology and Venereology (EADV) Congress that, for the third time in its history, was ...

Most conventional treatments produce limited results ... improvement in patients with chronic moderate-to-severe plaque psoriasis involving the hands and feet. The 12-week study was the first ...

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

Generally speaking, PASI is used for moderate to severe cases of plaque psoriasis and when you're treated with biologic drugs such as Humira (adalimumab) or Cimzia (certolizumab pegol). The PASI ...